ChromaDex (NASDAQ:CDXC) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of ChromaDex (NASDAQ:CDXC) in a research note issued to investors on Friday. The brokerage set a “buy” rating on the stock.

CDXC has been the topic of a number of other reports. LADENBURG THALM/SH SH boosted their target price on shares of ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a report on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of ChromaDex in a research note on Monday, March 17th.

ChromaDex Price Performance

The company has a market capitalization of $611.50 million, a PE ratio of 787.29 and a beta of 2.21. The stock has a fifty day simple moving average of $6.16 and a two-hundred day simple moving average of $5.44. ChromaDex has a 1 year low of $2.31 and a 1 year high of $9.18.

Institutional Investors Weigh In On ChromaDex

Several hedge funds and other institutional investors have recently made changes to their positions in CDXC. USA Financial Formulas bought a new position in ChromaDex during the 4th quarter valued at about $25,000. State of Wyoming purchased a new position in shares of ChromaDex during the fourth quarter valued at approximately $39,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of ChromaDex during the fourth quarter valued at approximately $53,000. Truist Financial Corp bought a new position in shares of ChromaDex during the fourth quarter valued at approximately $54,000. Finally, FMR LLC purchased a new stake in shares of ChromaDex in the third quarter worth approximately $55,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.